Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)

Simona Gatto, Greg Ball, Francesco Onida, Hagop M. Kantarjian, Elihu H. Estey, Miloslav Beran

Research output: Contribution to journalArticle

Abstract

Prospective analysis of the importance of the plasma levels of β-2 microglobulin (B2M) in 553 patients with myelodysplastic syndrome (MDS) found that B2M is an independent prognostic variable for survival with weighted significance second only to the karyotype. The incorporation of the B2M covariate into risk assessment of MDS patients added significantly to the power of the IPSS to stratify MDS patients into risk categories. Our results further document that the 2 objectively measured covariates that display the highest power to predict survival, that is, karyotype and B2M, can alone be used for risk stratification. While the results must be verified in an independent and comparable population, our data strongly recommend routine measurement of B2M in patients with MDS.

Original languageEnglish
Pages (from-to)1622-1625
Number of pages4
JournalBlood
Volume102
Issue number5
DOIs
Publication statusPublished - Sep 1 2003

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)'. Together they form a unique fingerprint.

  • Cite this